Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Abstract

The proliferation of "ultra-expensive" drugs has sparked debate on their sustainability and affordability. Medicare Part D's share of annual spending on these drugs increased by 1,170 percent between 2012 and 2018, largely because the number of beneficiaries receiving them increased during this period.